Cancer multidrug resistance-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs

International Journal of Cardiology

Volumn 176, Issue 3, 2014, Pages 1306-1308

  Patanè, Salvatore ^a  

^a Cardiologia Ospedale San Vincenzo   (Italy)

Author keywords

Cancer chemotherapy; Cancer multidrug resistance (CMDR); Cardio oncology; Cardiotoxicity

Indexed keywords

CARDIOVASCULAR AGENT;

ANIMAL; CARDIOVASCULAR SYSTEM; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG INTERACTION; DRUG RESISTANCE; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; NEOPLASMS; PHYSIOLOGY; PROCEDURES;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR SYSTEM; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

EID: 84908247697     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.158     Document Type: Article

References (92)

1. E. Conti, A. Romiti, and M.B. Musumeci Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors Int J Cardiol 167 6 Sep 10 2013 2421 2429
2. S. Rateesh, S.A. Luis, C.R. Luis, B. Hughes, and M. Nicolae Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge? Int J Cardiol 172 2 Mar 15 2014 e331 e333
3. S. Kurisu, T. Iwasaki, K. Ishibashi, N. Mitsuba, Y. Dohi, and Y. Kihara Comparison of treatment and outcome of acute myocardial infarction between cancer patients and non-cancer patients Int J Cardiol 167 5 Sep 1 2013 2335 2337
4. J.M. Scott, L.W. Jones, and W.E. Hornsby Cancer therapy-induced autonomic dysfunction in early breast cancer: implications for aerobic exercise training Int J Cardiol 171 2 Feb 1 2014 e50 e51
5. S. Claridge, A. Chakrabarti, K. Greaves, and C.J. Boos Successful use of trastuzumab following cardiac resynchronisation therapy Int J Cardiol 166 2 Jun 20 2013 e33 e34
6. M. Lotrionte, G. Palazzoni, and A. Abbate Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue doppler imaging Evaluation) randomized pilot study Int J Cardiol 167 3 Aug 10 2013 1055 1057
7. M.G. Kaya, M. Ozkan, and O. Gunebakmaz Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study Int J Cardiol 167 5 Sep 1 2013 2306 2310
8. K.L. Wang, C.J. Liu, and T.F. Chao Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis Int J Cardiol 167 5 Sep 1 2013 2162 2166
9. Y.F. Hu, C.J. Liu, and P.M. Chang Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients Int J Cardiol 165 2 May 10 2013 355 357
10. A. Budaj-Fidecka, M. Kurzyna, and A. Fijałkowska In-hospital major bleeding predicts mortality in patients with pulmonary embolism: an analysis of ZATPOL Registry data Int J Cardiol 168 4 Oct 9 2013 3543 3549
11. P. Pugliatti, R. Donato, G. Di Bella, S. Carerj, and S. Patanè Contrast-enhancing right atrial thrombus in cancer patient Int J Cardiol 173 3 May 15 2014 e35 e37
12. S. Grover, D.P. Leong, and A. Chakrabarty Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and biochemical markers Int J Cardiol 168 6 Oct 15 2013 5465 5467
13. W. Jurczak, S. Szmit, and M. Sobociński Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study Int J Cardiol 168 6 Oct 15 2013 5212 5217
14. C. Lestuzzi Cardioncology, oncocardiology. Are we barking up the wrong tree? Int J Cardiol 167 2 Jul 31 2013 307 309
15. P. Pugliatti, R. Donato, C. Zito, S. Carerj, and S. Patanè Cardio inhibitory vasovagal syncope in a cancer patient Int J Cardiol 174 2 Jun 15 2014 e64 e65
16. P. Pugliatti, C. De Gregorio, and S. Patanè The chance finding of echocardiographic complications of infective endocarditis Int J Cardiol 161 3 Nov 29 2012 e50 e51
17. S. Patanè HERG-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs Int J Cardiol 176 3 Aug 2 2014 1085 1088
18. Y. Elkina, S. Palus, and A. Tschirner Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia Int J Cardiol 170 2 Dec 10 2013 160 166
19. J. Springer, A. Tschirner, K. Hartman, S. von Haehling, S.D. Anker, and W. Doehner The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy Int J Cardiol 168 4 Oct 9 2013 3527 3531
20. S. Palus, S. von Haehling, and V.C. Flach Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia Int J Cardiol 168 4 Oct 9 2013 3412 3418
21. V. Avbelj, and R. Trobec A closer look at electrocardiographic P waves before and during spontaneous cardioinhibitory syncope Int J Cardiol 166 3 Jul 1 2013 e59 e61
22. W.J. Jang, H.R. Yim, S.H. Lee, S.J. Park, J.S. Kim, and Y.K. On Prognosis after tilt training in patients with recurrent vasovagal syncope Int J Cardiol 168 4 Oct 9 2013 4264 4265
23. K.P. Loh, and O. Ogunneye Malignant cardioinhibitory vasovagal syncope - an uncommon cardiovascular complication of Roux-en-Y gastric bypass surgery: the fainting syndrome! Int J Cardiol 164 3 Apr 15 2013 e38 e39
24. S. Patanè, and F. Marte Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system Eur Heart J 30 10 May 2009 1169 1170
25. M. Arcopinto, C.A. Cella, and R. Wesolowski Primary prevention of cancer-related thrombosis: special focus on ambulatory patients Int J Cardiol 173 3 May 15 2014 583 584
26. S. Patanè Breast cancer treatment cardioprotective strategies: the King is naked J Am Heart Assoc 2014 http://www.jaha.ahajournals.org/content/3/2/e000665/reply [Published July 22 2014]
27. D. Cardinale A new frontier: cardio-oncology Cardiologia Sep 41 9 1996 887 891
28. S. Patanè, and F. Marte Prostate-specific antigen kallikrein and acute myocardial infarction: where we are. Where are we going? Int J Cardiol 146 1 Jan 7 2011 e20 e22
29. S. Patanè, and F. Marte Prostate-specific antigen and acute myocardial infarction: a possible new intriguing scenario Int J Cardiol 134 3 May 29 2009 e147 e149
30. S. Patanè Prostate-specific antigen kallikrein and the heart World J Cardiol 1 1 Dec 31 2009 23 25
31. M. Scarano, F. Pezzuoli, G. Torrisi, G.M. Calvagna, and S. Patanè Cardiovascular implantable electronic device infective endocarditis Int J Cardiol 173 3 May 15 2014 e38 e39
32. S. Patanè Is there a need for bacterial endocarditis prophylaxis in patients undergoing urological procedures? J Cardiovasc Transl Res 7 3 Apr 2014 369 371
33. S. Patanè Is there a need for bacterial endocarditis prophylaxis in patients undergoing gastrointestinal endoscopy? J Cardiovasc Transl Res 7 3 Apr 2014 372 374
34. S. Patanè A dark side of the cardio-oncology: the bacterial endocarditis prophylaxis Int J Cardiol 157 3 Jun 14 2012 448 449
35. S. Patanè Cardiotoxicity: cisplatin and long term cancer survivors Int J Cardiol 175 1 Jul 15 2014 201 202
36. S. Patanè A challenge in cardiology: the oncosurgery Int J Cardiol 174 2 Jun 15 2014 411 412
37. S. Patanè Insights into cardio-oncology: adrenergic receptor signaling and pathways in breast cancer Curr Med Res Opin Jun 26 2014 1 2
38. S. Patanè, F. Marte, M. Sturiale, and G. Dattilo ST-segment elevation and diminution of prostate-specific antigen in a patient with coronary spasm and without significant coronary stenoses Int J Cardiol 148 2 Apr 14 2011 e31 e33
39. Y. Ozkanlar, M.S. Aktas, and M. Turkeli Effects of ramipril and darbepoetin on electromechanical activity of the heart in doxorubicin-induced cardiotoxicity Int J Cardiol 173 3 May 15 2014 519 521
40. S. Patanè Cardiotoxicity: Anthracyclines and long term cancer survivors Int J Cardiol 176 3 2014 1329 1331
41. S. Patanè Heart failure and breast cancer: emerging controversies regarding some cardioprotective strategies J Card Fail 20 6 Jun 2014 456 457
42. L. Zinzi, E. Capparelli, M. Cantore, M. Contino, M. Leopoldo, and N.A. Colabufo Small and innovative molecules as new strategy to revert MDR Front Oncol 4 Jan 21 2014 2 [eCollection 2014. Review]
43. A.E. Stacy, P.J. Jansson, and D.R. Richardson Molecular pharmacology of ABCG2 and its role in chemoresistance Mol Pharmacol 84 5 Nov 2013 655 669
44. Z. Binkhathlan, and A. Lavasanifar P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives Curr Cancer Drug Targets 13 3 Mar 2013 326 346 [Review]
45. L.Y. Chiu, J.L. Ko, Y.J. Lee, T.Y. Yang, Y.T. Tee, and G.T. Sheu L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines Toxicol Lett 192 3 Feb 15 2010 408 418
46. A. Dueñas-González, P. García-López, L.A. Herrera, J.L. Medina-Franco, A. González-Fierro, and M. Candelaria The prince and the pauper. A tale of anticancer targeted agents Mol Cancer 7 Oct 23 2008 82 [Review]
47. J. Bilbro, M. Mart, and N. Kyprianou Therapeutic value of quinazoline-based compounds in prostate cancer Anticancer Res 33 11 Nov 2013 4695 4700 [Review]
48. I. Staudacher, J. Jehle, and K. Staudacher HERG K + channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells PLoS One 9 2 Feb 6 2014 e88164 [eCollection 2014]
49. K. Takara, T. Sakaeda, and M. Kakumoto Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport Oncol Res 17 11-12 2009 527 533
50. A. Petty, E. Myshkin, and H. Qin A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo PLoS One 7 8 2012 e42120
51. F.Z. El Sharkawi, H.A. El Shemy, and H.M. Khaled Possible anticancer activity of rosuvastatine, doxazosin, repaglinide and oxcarbazepin Asian Pac J Cancer Prev 15 1 2014 199 203
52. S.W. Lee, J.W. Lee, J.H. Chung, and J.K. Jo Expression of heat shock protein 27 in prostate cancer cell lines according to the extent of malignancy and doxazosin treatment World J Mens Health 31 3 Dec 2013 247 253
53. S.S. Kim, H.J. Cho, J.M. Cho, J.Y. Kang, H.W. Yang, and T.K. Yoo Dual silencing of Hsp27 and c-FLIP enhances doxazosin-induced apoptosis in PC-3 prostate cancer cells Scientific World Journal 2013 Jun 19 2013 174392
54. P.J. Hensley, A. Desiniotis, C. Wang, A. Stromberg, C.S. Chen, and N. Kyprianou Novel pharmacologic targeting of tight junctions and focal adhesions in prostate cancer cells PLoS One 9 1 Jan 31 2014 e86238
55. F. Klepsch, P. Chiba, and G.F. Ecker Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein PLoS Comput Biol 7 5 May 2011 e1002036
56. J. Shao, and G. Feng Selective killing effect of oxytetracycline, propafenone and metamizole on A549 or Hela cells Chin J Cancer Res 25 6 Dec 2013 662 670
57. M. McCarthy, G. Auda, and S. Agrawal In vivo anticancer synergy mechanism of doxorubicin and verapamil combination treatment is impaired in BALB/c mice with metastatic breast cancer Exp Mol Pathol 97 1 Aug 2014 6 15
58. J. Huang, T. Zhang, and K. Ma Clinical evaluation of targeted arterial perfusion of verapamil and chemotherapeutic drugs in interventional therapy of advanced lung cancer Cancer Chemother Pharmacol 72 4 Oct 2013 889 896
59. B. Pająk, E. Kania, B. Gajkowska, and A. Orzechowski Verapamil-induced autophagy-like process in colon adenocarcinoma COLO 205 cells; the ultrastructural studies Pharmacol Rep 64 4 2012 991 996
60. Y. Chen, X.L. Zheng, and D.L. Fang Dual agent loaded PLGA nanoparticles enhanced antitumor activity in a multidrug-resistant breast tumor eenograft model Int J Mol Sci 15 2 Feb 18 2014 2761 2772
61. Q. Wan, Y.X. Chu, A. Zheng, X.J. Liu, and W.C. Wu Effects of verapamil on the proliferation and migration of cervical cancer cells Sichuan Da Xue Xue Bao Yi Xue Ban 42 1 Jan 2011 78 81
62. M. Tsubaki, M. Komai, and T. Itoh By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells Leuk Res 38 1 Jan 2014 121 130
63. M. Kakumoto, T. Sakaeda, and K. Takara Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil Cancer Sci 94 1 Jan 2003 81 86
64. K. Takara, T. Sakaeda, and K. Okumura Carvedilol: a new candidate for reversal of MDR1/P-glycoprotein-mediated multidrug resistance Anticancer Drugs 15 4 Apr 2004 303 309
65. N.G. Mehta, and M. Mehta Overcoming multidrug-resistance in cancer: statins offer a logical candidate Med Hypotheses 74 2 Feb 2010 237 239
66. M. Jafari, M. Rezaei, H. Kalantari, and M. Hashemitabar Determination of cell death induced by lovastatin on human colon cell line HT29 using the comet assay Jundishapur J Nat Pharm Prod 8 4 Nov 2013 187 191
67. R.A. Siddiqui, K.A. Harvey, Z. Xu, S.K. Natarajan, and V.J. Davisson Characterization of lovastatin-docosahexaenoate anticancer properties against breast cancer cells Bioorg Med Chem 22 6 Mar 15 2014 1899 1908
68. C.A. Goard, R.G. Mather, and B. Vinepal Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents Int J Cancer 127 12 Dec 15 2010 2936 2948
69. E. Sieczkowski, C. Lehner, P.F. Ambros, and M. Hohenegger Double impact on P-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells Int J Cancer 126 9 May 1 2010 2025 2035
70. J. Follet, L. Corcos, and G. Baffet The association of statins and taxanes: an efficient combination trigger of cancer cell apoptosis Br J Cancer 106 4 Feb 14 2012 685 692
71. A.H. Mohammadpour, H. Falsoleiman, J. Shamsara, G. Allah Abadi, R. Rasooli, and M. Ramezani Pentoxifylline decreases serum level of adhesion molecules in atherosclerosis patients Iran Biomed J 18 1 2014 23 27
72. S. Champion, N. Lapidus, G. Cherié, V. Spagnoli, J. Oliary, and A.C. Solal Pentoxifylline in heart failure: a meta-analysis of clinical trials Cardiovasc Ther 32 4 Aug 2014 159 162
73. I. Kupsáková, A. Rybár, and P. Docolomanský Reversal of P-glycoprotein mediated vincristine resistance of L1210/VCR cells by analogues of pentoxifylline. A QSAR study Eur J Pharm Sci 21 2-3 Feb 2004 283 293
74. P. Docolomanský, I. Fialová, M. Barancík, A. Rybár, and A. Breier Prolongation of pentoxifylline aliphatic side chain positively affects the reversal of P-glycoprotein-mediated multidrug resistance in L1210/VCR line cells Gen Physiol Biophys 24 4 Dec 2005 461 466
75. M. Barancik, V. Bohacova, L. Gibalova, J. Sedlak, Z. Sulova, and A. Breier Potentiation of anticancer drugs: effects of pentoxifylline on neoplastic cells Int J Mol Sci 13 1 2012 369 382
76. M. Sztiller-Sikorska, K. Koprowska, K. Majchrzak, M. Hartman, and M. Czyz Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells PLoS One 9 3 Mar 3 2014 e90783 [eCollection 2014]
77. P.N. Goel, and R.P. Gude Delineating the anti-metastatic potential of pentoxifylline in combination with liposomal doxorubicin against breast cancer cells Biomed Pharmacother 68 2 Mar 2014 191 200
78. P.N. Goel, and R.P. Gude Pentoxifylline regulates the cellular adhesion and its allied receptors to extracellular matrix components in breast cancer cells Biomed Pharmacother 68 1 Feb 2014 93 99
79. G. Savarese, G. Rosano, and C. D'Amore Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis Int J Cardiol 169 4 Nov 15 2013 262 270
80. S.A. Shah, G. Koyama, D. Da Costa, P. McGregor, and M. Kolasa Combination use of ranolazine with dofetilide for the maintenance of atrial fibrillation Int J Cardiol 172 3 Apr 1 2014 e428 e429
81. M.P. van den Berg, F. van den Heuvel, J.P. van Tintelen, P.G. Volders, and I.C. van Gelder Successful treatment of a patient with symptomatic long QT syndrome type 3 using ranolazine combined with a beta-blocker Int J Cardiol 171 1 Jan 15 2014 90 92
82. F. Corradi, L. Paolini, and R. De Caterina Ranolazine in the prevention of anthracycline cardiotoxicity Pharmacol Res 79 Jan 2014 88 102
83. M. Tarapués, G. Cereza, A.L. Arellano, E. Montané, and A. Figueras Serious QT interval prolongation with ranolazine and amiodarone Int J Cardiol 172 1 Mar 1 2014 e60 e61
84. D.A. Pierce, and A.M. Reeves-Daniel Ranolazine-tacrolimus interaction Ann Pharmacother 44 11 Nov 2010 1844 1849
85. M. Jerling Clinical pharmacokinetics of ranolazine Clin Pharmacokinet 45 5 2006 469 491 [Review]
86. [No authors listed] Ranolazine: new drug. Stable angina: not worth the risk Prescrire Int 18 102 Aug 2009 148-7
87. M.B. Djamgoz, and R. Onkal Persistent current blockers of voltage-gated sodium channels: a clinical opportunity for controlling metastatic disease Recent Pat Anticancer Drug Discov 8 1 Jan 1 2013 66 84 [Review]
88. Y. Chen, M. Scully, G. Petralia, and A. Kakkar Binding and inhibition of drug transport proteins by heparin: a potential drug transporter modulator capable of reducing multidrug resistance in human cancer cells Cancer Biol Ther 15 1 Jan 2014 135 145
89. A. Angelini, C. Di Febbo, and G. Ciofani Inhibition of P-glycoprotein-mediated multidrug resistance by unfractionated heparin: a new potential chemosensitizer for cancer therapy Cancer Biol Ther 4 3 Mar 2005 313 317
90. M. Carrett-Dias, A.P. Votto, and M. Filgueira Dde Anti-MDR and antitumoral action of acetylsalicylic acid on leukaemic cells Biosci Rep 31 5 Oct 1 2011 391 398
91. A.G. Speers, B.A. Lwaleed, J.M. Featherstone, B.J. Sallis, and A.J. Cooper Furosemide reverses multidrug resistance status in bladder cancer cells in vitro J Clin Pathol 59 9 Sep 2006 912 915
92. S.A. Francis, S. Cheng, C.L. Arteaga, and J. Moslehi Heart failure and breast cancer therapies: moving towards personalized risk assessment J Am Heart Assoc 3 1 Feb. 28, 2014 e000780